Regeneron Pharms beats by $0.69, beats on revs
- Reports Q3 (Sep) earnings of $3.90 per share, $0.69 better than the Capital IQ Consensus of $3.21; revenues rose 56.7% year/year to $1.14 bln vs the $1.05 bln Capital IQ Consensus.
- REGN2222, an antibody targeting the respiratory syncytial virus, entered Phase 3 clinical development in the third quarter of 2015.
- EYLEA U.S. net product sales: 50% - 55% growth over 2014. Capital expenditures: $625 mln - $675 mln (previously $675 mln - $750 mln).